AN-788 explained

AN-788, also known as NSD-788, is an experimental medication which was originated by NeuroSearch and is under development by Aniona and Saniona for the treatment of major depressive disorder.[1] [2] [3] It was also under development for anxiety disorders, but development for this indication was discontinued. The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI). As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder.[4]

See also

Notes and References

  1. Web site: Initiator Pharma. 8 November 2018 .
  2. Shao L, Li W, Xie Q, Yin H . Triple reuptake inhibitors: a patent review (2006 - 2012) . Expert Opinion on Therapeutic Patents . 24 . 2 . 131–154 . February 2014 . 24289044 . 10.1517/13543776.2014.859676 . 1825304 .
  3. Book: Bang-Anderssen B, Bøgesø KP, Kehler J, Sánchez C . New Trends in Antidepresent Drug Research . Ecker GF, Clausen RP, Sitte HH . Transporters as Drug Targets . https://books.google.com/books?id=eVO9DQAAQBAJ&pg=PA36. 16 December 2016. Wiley. 978-3-527-67951-5. 36–.
  4. Web site: Initiator Pharma signs option agreement for Phase 2 ready drug candidate. 2022-02-08. News Powered by Cision. 8 November 2018 . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "AN-788".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.